Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins
PR92181
FREIBURG, Germany, Oct. 12, 2021 /PRNewswire=KYODO JBN/ --
Eleva, a manufacturer of superior biologics, is entering clinical phases with
its own drug candidates, such as immune-regulating factor H, as well as in
collaboration with pharmaceutical partners. Its moss-based platform is ideally
suited to produce difficult-to-express but therapeutically promising drug
candidates.
Its recently expanded production capacity enables Eleva to conduct clinical
studies of its drug candidates. Among the first ones is factor H which will be
developed through phase II. Up to 2,500 l will be produced in state-of-the-art
single-use reactors at a GMP site.
Eleva's moss-based platform offers unique advantages for recombinant protein
development, such as:
- Moss glycostructure naturally lacks core á-1,6 fucose – a known allergen –
while any other glycans can be "humanized". This leads to excellent organ
uptake.
- Being a plant, it will not be contaminated with animal pathogens, which
eliminates the need for antibiotics.
- The moss production system, haploid by nature, is based on an intact
organism, not on cell cultures. This guarantees exceptionally stable
modifications.
Eleva is leveraging those advantages to produce complex proteins for future
therapies, such as 2nd generation oncological therapeutics, or
virus-like-particles (VLP) for vaccine development.
Ralf Smit, CBO of Eleva: "With production scaling up, we can now offer to
develop difficult-to-express therapeutic proteins in collaboration with
partners in the pharmaceutical industry. We look forward to our moss platform
unlocking the very promising potential of complex candidates for the benefit of
patients."
About Eleva
Based in Freiburg, Germany, Eleva develops novel biological therapies with its
pharmaceutical partners. The privately-held company leverages its unique
moss-based production platform to produce supreme biologics like antibodies,
replacement enzymes, or fusion toxins. Eleva has successfully developed drug
candidates into clinical phases.
Press contact
eleva GmbH
Fabienne Zeitter
pr@elevabiologics.com
Phone: +49 761 470 990
www.elevabiologics.com
Source: eleva GmbH
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。